Earliest Genetic Diagnosis Prehistoric DNA Romito

Ancient DNA Reveals Rare Genetic Growth Disorder in 12,000-Year-Old Mother and Daughter

Researcher Identify Rare Inherited Growth Disorder in a Prehistoric Mother and Daughter

Researchers from the University of Vienna, working alongside Liège University Hospital Center, have identified genetic mutations associated with a rare inherited growth disorder in two prehistoric people dating back over 12,000 years. Through the analysis of ancient DNA alongside modern clinical genetic techniques, the team diagnosed the condition in a mother and daughter interred together in southern Italy. Their study, published in the New England Journal of Medicine, highlights the growing power of paleogenomics to reveal both ancient population histories and rare genetic conditions.

Related science and archaeology coverage:

Human evolution and ancient discoveries

Grotta del Romito burial revisited

The discovery follows a renewed investigation of a famous Upper Palaeolithic burial site uncovered in 1963 at Grotta del Romito. For decades, researchers have debated the meaning of the burial and the unusual skeletal traits observed, with lingering uncertainty surrounding the pair's relationship and the biological cause of their reduced height.

Environmental and prehistoric context:

Ancient environments and human adaptation

A Remarkable Double Burial Raises Long-Standing Questions

The Romito Burial Explained

The two individuals were buried together in a striking embrace. The younger figure, known as "Romito 2", an adolescent with markedly shortened limbs and long believed to be male, was found resting in the arms of "Romito 1", previously identified as an adult woman. Careful examination revealed no evidence of injury or violent death.

Romito 2 is estimated to have stood around 110 cm tall, a stature consistent with a rare skeletal condition known as acromesomelic dysplasia, although this diagnosis could not be confirmed from bone evidence alone. Romito 1 was also notably short for the era, measuring approximately 145 centimeters.

For decades, scholars have debated:

• The biological sex of both individuals
• Their familial relationship
• Whether a shared medical condition explained their reduced height

Related biological variation insights:

Growth patterns in human and animals

Ancient DNA Unlocks Family relationship and Genetic Cause

To resolve these questions, researchers extracted ancient DNA from the petrous portion of the temporal bone in both individuals, an area known for exceptional genetic preservation. The analysis confirmed a first-degree biological relationship.

The team then examined genes linked to skeletal development, comparing the detected variants with modern clinical databases. This interdisciplinary investigation brought together:

• Paleogenomics
• Clinical genetics
• Physical anthropology

The research involved experts from the University of Vienna alongside collaborators in Italy, Portugal and Belgium.

Scientific methods and health genetics:

Genetics and inherited conditions

Earliest Genetic Diagnosis Ever Identified in Humans

The genetic analysis revealed that both individuals were female and closely related at the first-degree level, most likely a mother and her daughter.

In the younger individual, Romito 2, researchers identified a homozygous mutation in the NPR2 gene, a gene known to play a crucial role in skeletal development.

This findings confirmed a diagnosis of acromesomelic dysplasia, Maroteaux type — a very rare inherited condition marked by:

• Extreme short stature
• Pronounced limb shortening

Genetic evidence from Romito 1 showed that she carried a single altered copy of the same gene, a variant typically associated with a milder reduction in height.

Rare Diseases Have Roots in Human History

Ron Pinhasi of the University of Vienna, who co-led the research, says the use of ancient DNA is transforming how scientists interpret the past.

"By analyzing genetic material from prehistoric individuals, we can now pinpoint specific mutations," he explains. "This allows us to trace how far back rare genetic conditions extend and may even reveal variants that have never been documented before."

Daniel Fernandes of the University of Coimbra, the study's lead author, adds that confirming both individuals as female and closely related reframes the burial as a rare familial genetic case.

"The milder short stature of the older woman is consistent with a heterozygous mutation," he says, "demonstrating how the same gene could affect members of a prehistoric family in different ways."

Medical history and rare conditions:

Understanding rare diseases

Clinical Insights From Prehistoric Genetics

From a clinical perspective, the findings underline the long history of rare diseases. Adrian Daly of Li ège University Hospital Center, a co-leader of the study, notes:

"Rare genetic disorders are not a modern development. They have existed throughout human history and understanding their past can help us recognize and interpret these conditions today."

Evidence of Compassion and Long-Term Social Care

Despite profound physical limitations, Romito 2 lived into adolescence or possible adulthood, pointing to long-term care within her community.

Alfredo Coppa of Sapienza University of Rome, a co-leader of the study, says her survival would almost certainly have depended on sustained support.

"We believe she was cared for by her group over many years, receiving assistance with food and movement in what would have been a demanding environment," he explains.

Source

Social behaviour and care in early societies:

Cooperative behaviour in animals

Toxic Masculinity Manosphere Study Male Idenity

Is All Masculinity Toxic? New Study Break Down Five Male Identity Types

A growing online subculture known as the "manosphere" has emerged across forums and social media, promoting a hardline view of masculinity rooted in dominance, misogyny and hostility towards feminism—traits widely described as toxic.

Researchers Flag Lack of Clear Evidence

Amid rising concern over the influence of such movements, researchers noted a striking lack of solid evidence clearly defining or measuring what toxic masculinity actually looks like.

Related social research and culture coverage

Large-Scale Study of Masculinity in New Zealand

To address this gap, the team analyzed nationwide data from a representative sample of 15,808 heterosexual men in New Zealand, aged between 18 and 99. They assessed levels of gender identification alongside attitudes including sexism, sexual prejudice, narcissism and support for social dominance, identifying five distinct profiles. The largest group, representing 35.4% of participants, showed largely non-toxic patterns.

Gender Identity Not Strongly Linked to Toxic Behaviour

One of the study's more unexpected conclusions was that a strong sense of gender identity was not closely linked to toxic behaviour. Even among men whose views aligned with patterns associated with toxic masculinity, being male played only a slightly greater role in their self-identity than it did for others.

The researchers stress that identifying strongly as "manly" does not, in itself, make someone toxic. The findings were published in Psychology of Men & Masculinities.

Environment related coverage

Is All Masculinity Toxic?

Origins of the Term

The term toxic masculinity was first introduced in 1990 by psychologist Shepherd Bliss as part of the mythopoetic men's movement. He used it to describe behaviours that harm women, children and other men, pointing to a damaging aspect of male psychology. Since the rise of the Metoo movement, the meaning of the term has broadened significantly.

How the Meaning of Toxic Masculinity Has Expanded

Today, it is often used as an umbrella label covering issues ranging from explicit misogyny and rape culture to limits on women's reproductive rights, mansplaining and men's avoidance of domestic labour.

Concerns Over Vague Use of the Term

Despite its widespread use in public debate—and more than 10,000 academic articles published since 2020 —many studies fail to measure toxic masculinity empirically. Instead, the term is frequently employed as a general expression of disapproval.

Researchers warn that treating masculinity as inherently toxic may be counterproductive, particularly at a time when many men face serious challenges around health and wellbeing.

Health and wellbeing perspectives

Traits Used to Measure Problematic Masculinity

To address this gap, the researchers examined how widespread different forms of problematic masculinity are by analyzing eight core traits and beliefs:

• Centrality of gender identity
• Sexual prejudice
• Disagreeableness
• Narcissism
• Hostile sexism
• Benevolent sexism
• Opposition to domestic violence prevention
• Support for social dominance

Data Source and Analytical Approach

The team drew on data from the long-running New Zealand Attitudes and Values Study (NZAVS) and applied latent profile analysis, a statistical technique used to identify distinct groups within large datasets. this approach revealed five separate masculinity profiles.

More data-driven reporting

Five Distinct Masculinity Profiles Identified

The analysis showed:

• 35.4% fell into an atoxic category, showing consistently low levels across all harmful indicators
• 53.8% were grouped into two moderate profiles, with generally low-to-moderate scores that differed mainly in levels of sexual prejudice
• 7.6% fit a benevolent toxic profile, marked by high benevolent sexism alongside elevated sexual prejudice
• 3.2% fell into a hostile toxic category, marked by high levels of sexism, narcissism and opposition to efforts aimed at preventing domestic violence

Masculinity and Harm Are Not the Same

The findings further showed that a strong identification with being "manly" did not automatically signal problematic masculinity.

Researchers stressed the importance of distinguishing harmful expressions of masculinity from healthy and positive ones, noting that future studies using more diverse samples could help shape targeted interventions for different toxic masculinity profiles.

Source

Jelly Like Artificial Nerve Senses Human pain

Scientists Develop Jelly-Like Artificial Nerve That Can Sense Pain Like Humans

Artificial Nociceptors Inspired by the Human Body

Scattered throughout the human body are microscopic sensors known as nociceptors, which detect potentially harmful stimuli and relay warning signals to the brain and spinal cord, helping to prevent injury and tissue damage.

Breakthrough in Artificial Pain-Sensing Technology

In a recent breakthrough, researchers at Northeast Normal University in China developed a soft, jelly-like artificial pain-sensing nerve pathway using a memristor — a tiny electronic component capable of regulating electrical flow while retaining a memory of past currents.

Related science and environment coverage

How the Artificial Pain Sensor Works

Thanks to a property known as quantized conductance, in which electrical signals move in discrete steps rather than a continuous flow, the artificial receptor was able to register four graded pain responses, closely mirroring the human experience:

• No pain
• Mild pain
• Moderate pain
• Severe pain

Self-Healing and Bio-Inspired Capabilities

The bio-inspired receptor also demonstrated self-healing capabilities, showing an ability to repair physical damage and gradually diminish pain signals over time.

Researchers believe that replicating the body's natural pain-sensing mechanisms could open new frontiers in neuroprosthetics and enable more intuitive interactions between humans and machines.

The study has been published in the journal Advanced Functional Materials.

Health and neurotechnology insights

Get That Senses Pain at Different Levels

Limits of Earlier Artificial Nociceptors

Artificial nociceptors have been the subject of scientific research for many years. Early efforts relied on conventional semiconductor technology, but this approach required complex, bulky circuitry to replicate even the most basic human pain responses.

Role of Memristors in Pain Detection

The emergence of memristors marked a turning point, shifting attention away from traditional semiconductors towards compact, two-terminal devices well suited to brain-inspired computing. Using their unique switching behaviour, scientists have created artificial pain sensors that intensify their response to repeated stimulation, without becoming desensitized over time as natural pain receptors do.

Despite this progress, many existing artificial nociceptors still struggle to replicate graded pain levels and self-healing abilities, both of which are essential for realistic pain perception and recovery.

Testing Pain Sensitivity and Human-Like Responses

In this study, researchers achieved greater precision in pain sensing by combining two types of gelatin film:

• A 10 wt.% formulation for pressure detection
• A 1 wt.% formulation for the memristor

When linked in series, these components formed an artificial nerve pathway.

Pressure Testing and Pain Response Levels

To test its sensitivity, the team applied mechanical pressures ranging from 9 to 45 kPa (kilopascal), successfully identifying four distinct response levels, from no pain through to severe pain.

Demonstrating Self-Healing Ability

They also assessed the system's self-healing ability by introducing cuts up to 50.7 micrometers wide into the gelatin sensors. After heating the material to 60°C for 20 minutes, the damage vanished and the electrical performance returned to its original state.

Successful Testing in a Living Nervous System

The artificial pain sensor was linked to the sciatic nerve of an anaesthetized mouse. When pressure was applied, the device generated electrical signals that triggered muscle contractions, closely replicating a natural withdrawal response.

Implications for Human-Machine Interaction

The findings suggest that soft, jelly-like materials designed to imitate pain receptors could transform human-machine interfaces and support the development of more effective rehabilitation technologies for people recovering from injury.

Source

Acetaminophen Pregnancy Autism ADHD Lancet Study

Major Study Finds No Link Between Acetaminophen Use in Pregnancy and Autism or ADHD

Largest Review to Date Addresses Long-Standing Safety Concerns

A major new study has found no evidence that taking acetaminophen during pregnancy increases the likelihood of autism, ADHD or intellectual disability in children. Published in The Lancet Obstetrics, Gynecology & Women's Health, the research was led by scientists from City St George's, University of London.

Why the Study Was Conducted

The researchers examined data from 43 earlier studies in a detailed systematic review and meta-analysis, aiming to settle long-running questions about the drug's safety during pregnancy. The review was prompted by public concern after claims made in September 2025 suggested acetaminophen could harm children's neurodevelopment.

Related health and safety insights

Earlier Claims and Scientific Concerns

While some earlier studies hinted at slight associations with autism, the new analysis found these claims were often based on flawed evidence. Many failed to control for bias, used incomplete data or overlooked sibling comparisons — an essential step in separating drug effects from family-related influences.

How the Research Was Conducted

Review of High-Quality Studies

The researchers examined 43 of the highest-quality studies, using the most robust research methods available, to compare pregnancies in which mothers took acetaminophen with those in which the drug was not used.

More on medical research standards

Sibling-Comparison Analysis Explained

They combined findings from sibling-comparison studies, analyzing families where one child was exposed to acetaminophen in the womb and another was not. This powerful approach helps account for shared genetics, home environment and long-standing parental factors that standard observational studies often miss.

Large-Scale Data Strengthens Findings

In total, the sibling data covered:

• 262,852 children assessed for autism
• 335, 255 children assessed for ADHD
• 406, 681 children assessed for intellectual disability

The analysis confirmed that prenatal acetaminophen use was not associated with an increased risk of any of these conditions.

Expert Opinion: Acetaminophen Remains First-Line Treatment

Professor Asma Khalil, professor of obstetrics and maternal-fetal medicine at City St George's, University of London and the study's lead author, said the findings point away from acetaminophen as the cause of earlier reported risks. Instead, she explained, those links are more likely due to genetic predisposition or other maternal factors, such as fever or underlying pain.

"The message is clear," she said. "Acetaminophen remains a safe option in pregnancy when taken as recommended. It is the first-line treatment we advise for pregnant women experiencing pain or fever, and they should feel confident that they still have a safe way to manage their symptoms."

Pregnancy and maternal health resources

Quality Assessment and Long-Term Consistency

All studies were assessed using the Quality in Prognosis Studies (QUIPS) tool, which evaluates multiple aspects of study design to determine the risk of bias. Crucially, the lack of any association between prenatal acetaminophen use and autism, ADHD or intellectual disability remained consistent in the highest-quality studies and in those with follow-up periods exceeding five years.

Study Limitations Acknowledged

Researchers noted that the study was limited by gaps in the available data, which made it impossible to analyze smaller subgroups in sibling-comparison research. Too few studies provided information on:

• Trimester-specific use
• Sex of the child
• Frequency of acetaminophen intake

Medical Guidance and Public Health Implications

Even so, the findings align closely with recommendations from major medical bodies worldwide. The team hopes the strength of this comprehensive review will dispel ongoing concerns, warning that avoiding acetaminophen for significant pain or fever can expose both pregnant women and their babies to known dangers, particularly untreated maternal fever.

Source

More science-backed health news:

• https://fsnews365.blogspot.com/
• https://earthdayharshreality.blogspot.com/

Bat Borne Orthoreovirus Bangladesh

Bat-Borne Orthoreovirus Linked to Mysterious Respiratory and Brain Illness in Bangladesh

Infections disease specialists have traced a mysterious illness affecting five patients in Bangladesh to Pteropine orthoreoviruses (PRVs)—a newly emerging group of bat-borne pathogens. One of the patients later died after suffering from unexplained complications, raising fresh concerns over hidden viral threats.

This marks the first recorded instance of a bat-origin orthoreovirus, a double-stranded RNA virus, being linked to acute respiratory disease and encephalitis in humans in Bangladesh. The research has been published in the journal Emerging Infectious Diseases.

More public health and breaking science news

Raw Date-Palm Sap Identified as a Common Exposure

Investigators found that all five patients had recently consumed raw date-palm sap, a seasonal delicacy that bats frequently feed on during winter. The sap has already been identified as a transmission route for Nipah virus in the country.

Bats are recognized as natural hosts for a wide range of zoonotic viruses, including rabies, Nipah, Hendra, Marburg and SARS-1.

Environmental related coverage

Scientists Warn of Broader Zoonotic Spillover Risks

"Our research shows that the danger of zoonotic spillover linked to the consumption of raw date-palm sap goes well beyond Nipah virus," said Dr Nischay Mishra, Associate Professor of Epidemiology at the Center for Infection and Immunity, Columbia University Mailman School of Public Health, and the study's senior author.

He stressed the urgent need for broad-spectrum surveillance systems to detect and reduce public health threats posed by newly emerging bat-borne viruses.

Patients Initially Suspected of Nipah Virus Infection

The five patients, who hospitalized between 2022 and 2023, were initially suspected of having Nipah virus infection. However, laboratory tests repeatedly returned negative results, despite the patients displaying similar symptoms such as:

• Fever
• Vomiting
• Headaches
• Fatigue
• Excessive salivation
• Serious respiratory complications
• Neurological complications

Human Health and infectious disease insights

Advanced Viral Sequencing Reveals the Culprit

In the latest study, scientists carried out high-throughput, agnostic viral sequencing using the CII's VirCapSeq-VERT platform. Biological samples were analyzed from the five confirmed cases, alongside samples from more than 130 patients who had shown Nipah-like symptoms between 2006 and 2022.

The work formed part of a long-running Nipah virus surveillance programme led by:

• Bangladesh's Institute of Epidemiology, Disease Control and Research (IEDCR)
• The International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B)
• The US Centres for Disease Control and Prevention (CDC)

How VirCapSeq-VERT Detects Emerging Viruses

Dr Nishchay Mishra and his team employed VirCapSeq-VERT, a technology developed at the Centre for Infection and Immunity, to rapidly detect all known vertebrate-origin viral infections.

The system matches the sensitivity of gold-standard PCR testing, while allowing thousands of viruses to be screened simultaneously and delivering near-complete viral genome sequences.

Live Infectious Virus Confirmed in the Laboratory

Researchers also confirmed the presence of live, infectious virus through laboratory culture. All five patients suffered severe illness, although PRV infections reported in neighbouring countries have typically been milder, raising concerns that less serious cases in Bangladesh may be going undetected.

"This represents a new zoonotic spillover risk, causing respiratory and neurological complications following the consumption of raw date-palm sap, alongside the well-known threat of Nipah virus," said Dr Tahmina Shirin, Director of the Institute of Epidemiology, Disease Control and Research (IEDCR) and the National Influenza Centre (NIC) in Bangladesh.

Bats Near Patient Homes Identified as Likely Source

In more recent work, Mishra and his colleagues traced the source of infection by identifying genetically similar Pteropine orthoreoviruses in bats captured near the homes of the five patients in the Padma River Basin.

These findings, though yet to be published, strengthen the suspected animal-to-human link.

"This research offers vital evidence connecting bat reservoirs to human infection," said Ariful Islam, a bat-borne disease ecologist and epidemiologist at Charles Sturt University in Australia and co-first author of the study.

"We are now investigating how spillover occurs from bats to humans and domestic animals, and examining the wider ecology of emerging bat-borne viruses in communities along the Padma River Basin."

Technology Already Proven in Other Major Outbreak Investigations

In earlier work, Mishra and his colleagues used the same technology to:

• Uncover a previously unrecognized viral threat in transplant patients
• Identify neurological complications in an infant and COVID-19
• Trace an enterovirus infection responsible for a rare neurological disorder
• Determine the origins of chikungunya in Brazil

Beyond its use in research settings, VirCapSeq-VERT has now secured regulatory approval for clinical application.

Study Authorship

The study was co-first authored by Sharmin Sultana, Assistant Professor of Virology and Senior Scientific Officer at Bangladesh's Institute of Epidemiology, Disease Control and Research (IEDCR).

Source

More infectious disease and global health reporting

Human Brain Prefrontal Cortex Development Macaques

Why the Human Brain Develops Differently From Other Primates, New Research Reveals

The Human Brain's Unique Developmental Journey

The human brain stands as one of nature's most remarkable achievements, enabling advanced behaviours and cognitive skills that are not found in any other species. For generations, scientists have sought to uncover what sets the human brain apart and how it evolves throughout a person's lifetime.

In recent years, breakthroughs in technology and experimental methods have transformed neuroscience, allowing researchers to map brain structure and function with unprecedented precision. These advances are offering valuable insights into the biological roots of neuropsychiatric and neurodevelopmental conditions.

Comparing Human and Macaque Brain Development

A research team from Beijing Normal University, the Changping Laboratory and partner institutions has now compared the developmental trajectories of the human and macaque brains using cutting-edge genetic and molecular techniques. Their findings, published in Nature Neuroscience, reveal notable differences between the species, particularly showing that the human prefrontal cortex develops at a slower pace than that of macaques.

Related reading:

Brain and cognition insights

Mental health research

Decoding Prefrontal Cortex Development at Cellular Level

Decoding how the human prefrontal cortex (PFC) develops at the cellular and molecular level is key to understanding both human intelligence and vulnerability to neurological and neuropsychiatric conditions, the researchers explained.

Jiyao Zhang, Mayuqing Li and their team reported the creation of a unique comparative resource that captures gene activity, chromatin structure and spatial transcriptomic patterns in the postnatal PFC of humans and macaques, analyzed one cell at a time.

Mapping Brain Development at a Single-Cell Level

The study involved high-resolution mapping of brain development using tissue samples collected from the prefrontal cortex of humans and macaques at different postnatal stages. Human tissue was sourced from paediatric epilepsy patients undergoing medically necessary brain surgery.

The research team examined gene activity within individual cells extracted from the collected tissue, alongside chromatin accessibility, which indicates how open or closed DNA is inside each cell. Using spatial transcriptomics, they also charted gene expression across entire brain sections and identified the various cell types present.

According to the authors, these integrated analyses revealed species-specific developmental pathways for different cell populations, pinpointing critical periods and gene regulatory networks involved in synapse formation, synaptic pruning and gliogenesis.

Environmental science & evolution context

Human-Specific Brain Development Mechanisms Identified

The findings showed that the human prefrontal cortex develops over a longer timeframe than that of macaques. In addition, glial progenitor cells —steam-like cells that later give rise to specialized glial types—were found to proliferate more extensively in humans.

The researchers reported that they had identified regulatory mechanisms linked to the extended development of the human prefrontal cortex compared with that of macaques. They found that glial progenitor cells in humans display a greater capacity for proliferation, accompanied by distinctive gene expression patterns.

The study also pinpointed specific cell types and development lineages that appear most vulnerable to neurodevelopmental and neuropsychiatric disorders, with particular emphasis on transcription factors showing human-specific expression.

Insights That Could Deepen Understanding of Human Cognition

Zhang, Li and their colleagues uncovered a series of important findings that offer deeper insight into well-known functional differences between human brains and those of other primates. The team identified transcription factors that influence human brain development but appear absent in macaques, while also highlighting specific cell types in human tissue that are commonly affected in patients with certain neurological disorders.

"Our findings reveal human-specific regulatory programmes that extend postnatal cortical maturation through coordinated neuronal and glial development, with clear implications for cognition and neurodevelopmental disorders," the researchers wrote.

Looking ahead, these results could improve understanding of how the human brain matures and which molecular pathways are disrupted in neurodevelopmental and neuropsychiatric conditions, potentially opening the door to new preventive or therapeutic approaches.

Source

Psilocybin vs Cannabis OCD Treatment

Psilocybin Shows Greater Promise Than Cannabis for Treating OCD, Major Review Finds

New Scientific Review Reconsiders Future Treatments for Obsessive-Compulsive Disorder

A review led by scientists at McMaster University suggests that psilocybin may hold greater promise for treating obsessive-compulsive disorder than cannabinoid-based therapies.

Obsessive-compulsive disorder (OCD) is marked by relentless, intrusive thoughts and repetitive behaviours, often demanding lifelong management. Researchers note that the condition stems from a complex interplay of biological mechanisms, with disruptions in serotonin, dopamine and glutamate signaling thought to play a key role.

Standard treatment relies on selective serotonin reuptake inhibitors alongside cognitive behavioural therapy, particularly exposure and response prevention. However, as many as six in ten patients fail to respond adequately, leaving a substantial proportion living with treatment-resistant Obsessive-compulsive disorder (OCD).

Broader discussions on long-term mental health challenges and treatment resistance are frequently explored at Human Health Issues, which examines emerging research into chronic psychological conditions.

Psychedelics Re-Enter psychiatric Research

Over the past decade, psychedelics have re-entered psychiatric research, with growing attention on their potential influence over brain circuits linked to compulsive behaviour, emotional regulation and anxiety.

What the Scientists Examined

In a paper titled "New treatments for OCD? Evidence for cannabinoids and psychedelics", published in the Journal of Psychiatric Research, scientists carried out an extensive scoping review examining the role of psilocybin in obsessive-compulsive disorder, including cases resistant to conventional treatment.

The review drew on both published studies and grey literature, assessing evidence on cannabinoids and several psychedelic substances, including psilocybin, LSD, DMT and methylenedioxyphenethylamine. Much of the data stemmed from case reports and survey-based research, with only a handful of small clinical trials and very limited controlled studies available.

Cannabis Findings Split in OCD Patients

Mixed Outcomes From Medical Cannabis Use

Data collected via the Strainprint smartphone app followed 1,810 cannabis use sessions over a 31-month period among 87 OCD patients prescribed medicinal cannabis for obsessive-compulsive disorder. Users reported fewer intrusive thoughts in nearly 90% of sessions, reduced compulsive behaviours in over 95% and lower anxiety levels in close to 94%. By contrast, symptom worsening was uncommon, occurring in just 3% of intrusion reports, 2.3% of compulsions and 1.9% of anxiety cases.

On average, inhaled cannabis was linked to a 49% drop in intrusive thoughts, a 60% reduction in compulsions and a 52% decrease in anxiety. Higher CBD content and dosage were associated with greater improvements in compulsive behaviour only. While baseline ratings for intrusions and compulsions remained stable over time, anxiety levels prior to use showed a significant downward trend.

An Italian outpatient survey followed 70 individuals diagnosed with primary OCD under DSM-5 criteria, dividing participants into current users, former users and non-users of substances. Around 30% reported using substances to manage obsessive-compulsive symptoms, with cannabis cited by 10%. Only a small fraction of current or past cannabis users said the drug eased their symptoms, while nearly a quarter reported a worsening of OCD, largely linked to heightened anxiety.

Environmental and lifestyle factors affecting mental health outcomes are also discussed on Earth Day Harsh Reality, which connects planetary stressors with human wellbeing.

Psilocybin and Psychedelic Findings Show Stronger Signals

International and Clinical Evidence Emerges

An international retrospective study involving 174 people with OCD from France, Canada, Belgium, United States and Switzerland examined experiences with psychedelic substances. Of all drug categories assessed, classic psychedelics were the only ones consistently associated with meaningful symptom improvement.

Reports on duration were mixed: one-third of participants experienced benefits lasting longer than three months, while another third saw improvements fade within a week following psilocybin or LSD use. Greater symptom relief was linked to more intense and positively perceived psychedelic experiences.

Clinical Psilocybin Evidence Highlights Rapid Effects

Case Reports and Variable-Dose Studies

Clinical evidence on psilocybin has emerged from individual case reports, variable-dose studies and later controlled investigations. One widely cited case involved a 33-year-old man with treatment-resistant OCD who received psilocybin at 0.25 mg per kilogram, equivalent to 19.4 mg. His Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score fell sharply from 23 before dosing to just 2 within 48 hours, before reaching zero at the 12-week follow-up. The patient later reported feeling entirely free of OCD symptoms one year after treatment.

Further findings from a small variable-dose study involving nine individuals with treatment-resistant OCD showed immediate symptom reductions in all participants within 24 hours of at least one dose. Improvements ranged from 23 to 100%, with nearly 90% maintaining a minimum 25% reduction at 24 hours, and two-third sustaining a reduction of at least 50%. No clear relationship was found between dose size and compulsive symptom scores.

Controlled Psilocybin Trial Results

In a controlled within-subjects study, 18 adults with moderate to severe OCD received 10 mg of synthetic psilocybin and a 1 mg active control dose four weeks apart. Symptom scores at one, two and four weeks after the 10 mg dose were significantly improved compared with baseline, with the strongest effect observed after one week.

Findings from LSD-assisted psychotherapy involved two patients with severe, treatment-resistant OCD who received between one and five doses of LSD at levels of 100 to 200 micrograms. One individual entered remission, while the second experienced no improvement.

Clinical Limitations and the Path Forward

The current body of psychedelic research remains limited, relying heavily on small-scale studies and individual case reports, which restrict firm clinical conclusions. To date, there is little evidence to support cannabinoids as viable treatments for OCD, while psilocybin appears to offer more promise for those unresponsive to conventional therapies.

Positive psilocybin signals have already been reported in PTSD, anxiety and depression disorders that share features such as recurring intrusive thoughts. The inclusion of OCD strengthens the case for further investigation through larger randomized controlled trials, robust comparison groups and extended follow-up to determine lasting clinical benefit.

Source